J Urol: Cardiovascular incidence of GnRH agonants VS antagonists in patients with advanced prostate cancer and cardiovascular disease
-
Last Update: 2020-07-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- androgen deprivation therapy may increase the risk of cardiovascular diseaselimited data suggest that GnRH (gonadotropin-releasing hormone) antagonist may reduce the risk of cardiovascular disease compared to GnRH agonistswe conducted a Phase II randomized open-label study of men with prostate cancer and pre-existing cardiovascular disease, and randomly grouped them into a group of people who received GnRH agonisor or antagonist treatment for one yearthe main outcome of theis the endothelial function measured by the EndoPAT 2000 device (Itamar Medical, Caesarea, Israel)secondary outcome is a new cardiovascular eventtrack the development of cardiovascular disease in patients, defined as death, myocardial infarction, cerebrovascular events, transdermal angioplasty placed by coronary artery stents, or hospitalization for heart eventsresults, a total of 80 patients participated in the study, including 41 who received GnRH antagonists and 39 patients received agonistsbaseline characteristics are similar for each group of patientsdid not find a difference in the primary endpoint (endothelial function) between the groups (average sD reactive hyperemia index 2.07.15 vs 1.92-0.11, p-0.42), however, during the trial, 15 patients experienced new cardiovascular events (secondary endpoints)in 9 new major cardiovascular and cerebrovascular events, including 2 deaths, 1 myocardial infarction, 2 cerebrovascular events, 4 cases of transdermal angioplasty and insertion of coronary artery stents20% of patients who were randomly given GnRH agonists had major cardiovascular events, compared with only 3% of patients taking GnRH antagonists (P-0.013)the absolute risk of major cardiovascular events was reduced to 18.1% for 12 months of use with GnRH antagonists (95% CI 4.6-31.2, p-0.032)as far as we know, this is the first prospective study to test cardiovascular outcomes in prostate cancer patients treated with androgen deprivationthere is no difference between the main endpoints of thestudy arm However, secondary endpoints showed that patients treated with GnRH agonists had significantly more major cardiovascular and cerebrovascular events than those treated with GnRH antagonists these Phase II results suggest that for prostate cancer patients who already have cardiovascular disease, choosing androgen deprivation treatment may have different effects on heart outcomes
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.